Jaydip Mahata et al, International Journal of Pharmaceutical Sciences & Medicine (IJPSM), Vol.7 Issue. 5, May- 2022, pg. 72-86 ISSN: 2519-9889 Impact Factor: 5.721 © 2022, IJPSM All Rights Reserved, https://ijpsm.com/ 72 Formulation and Evaluation of Bilayer Tablet of Saxagliptin Jaydip Mahata*; Jeevan Patel; Ramakant Sharma; Dr. Rakesh Patel School of Pharmacy, Dr. A.P.J Abdul Kalam University, Indore DOI: 10.47760/ijpsm.2022.v07i05.007 ABSTRACT In the present study Saxagliptin 60mg tablets have been formulated and developed using direct compression and dry granulation technique, to provide a safe, highly effective method for treating congestive heart failure, edema and kidney disorder, while reducing undesirable adverse effects. Pre and post formulation parameters were studied for the formulated batches. The result of all the physical and in-vitro dissolution data concluded that bilayer tablet (I3,S9) was the most promising formulation. The trial conducted with the consecutive three batches for immediate release and sustained release revealed relative standard deviation below 2 %, indicative the insignificant batch-to-batch variation that can be overcome if processes are run out in a controlled manner. Using Crosspovidone as super disintegrate and HPMC as sustained release polymer blend would be cost effective and dissolution mediums 0.1N HCl would the ideal media for conducting dissolution studies. It was concluded that the bilayer tablet formulation can be act as a better tool for the successful administration of two or more drug which will remain stable for longer period of time. Keywords: Bilayer Tablet, Saxagliptin, sustained release polymer, super disintegrate, drug released. 1. INTRODUCTION Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic for the treatment of type 2 diabetes. DPP-4 inhibitors are a class of compounds that work by affecting the action of natural hormones in the body called incretins. Incretins decrease blood sugar by increasing consumption of sugar by the body, mainly through increasing insulin production in the pancreas, and by reducing production of sugar by the liver.